Benralizumab Hits Mark in Head-to-Head EGPA Vasculitis Trial ...Middle East

Medscape - News
In the study, adults with EGPA were randomized to a single 30-mg subcutaneous injection of benralizumab or three separate 100-mg subcutaneous injections of mepolizumab once every 4 weeks. MDedge News

Hence then, the article about benralizumab hits mark in head to head egpa vasculitis trial was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Benralizumab Hits Mark in Head-to-Head EGPA Vasculitis Trial )

Apple Storegoogle play

Last updated :

Also on site :